(zoster, vaccine live, attenuated [Oka/Merck], refrigerator-stable)
Shingles has been described as excruciating, intense, potentially debilitating, with nerve pain that can last for months or even years.
The only shingles vaccine that’s given as a single shot.
Learn more about insurance coverage for single‑shot ZOSTAVAX® II
See our resources section for more information on shingles, its causes, who is at risk and vaccination.
ZOSTAVAX® II does not protect everyone, so some people who get the vaccine may still get shingles. However, if you develop shingles despite being vaccinated, ZOSTAVAX® II can help reduce the intensity and duration of pain. ZOSTAVAX® II is indicated for the prevention of herpes zoster (shingles) and for immunization of individuals 50 years of age or older. ZOSTAVAX® II cannot be used to treat existing shingles or the pain associated with existing shingles. ZOSTAVAX® II has not been studied in individuals who have previously experienced an episode of herpes zoster. Side effects and allergic reactions can occur. The most common side effects were at the injection site and included redness, pain, swelling, hard lump, itching, warmth, and bruising. Headache and pain in the arm or leg were also reported. ZOSTAVAX® II should not be used if you have a blood disorder or any type of cancer that weakens your immune system, a weakened immune system as a result of a disease, medication, or other treatment, active untreated tuberculosis or if you are pregnant.
Merck Canada does not review or control the content of any non-Merck site. Merck Canada is not associated with this non-Merck website and cannot be held responsible for the accuracy, content, practices or standards of this website and for the consequences of any decision taken on the basis of the content featured on such website.